Shareholder
Wilsons Updated Research Report
Wilsons Equity Research has released an updated analysis on Hexima Limited, with a view on the potential for success in phase II. Wilsons maintains its OVERWEIGHT rating and a $0.75 12-month price target. View the full report (pdf)
ShareCafe Webinar 29 April 2022
Hexima CEO, Michael Aldridge, presented at the ShareCafe Hidden Gems Webinar on 29 April 2022 at 12:30pm AEST. Mr Aldridge provided a company overview and discussed its phase II clinical trial, including when the company is expecting results from the trial. This...
NailMail Q1 2022
Hexima is proud to release its “NailMail” quarterly activities report for the quarter ended 31 March 2022. Achievements for the quarter include: Appointed Mr Philip Rose as Chief Commercial Officer and strengthened the manufacturing team with the appointment of Mr Om...
Investor Webinar April 2022
Thank you to those that attended our Investor Webinar today, 5 April 2022 at 9:00 AM AEST. Hexima Chief Operating Officer, Dr Nicole van der Weerden, presented pezadeftide’s novel fungicidal mode of action which she recently shared at the annual meeting of the...
Presentation at American Academy of Dermatology March 2022
Pezadeftide Mode of Action Hexima is proud to present new data describing the unique mechanism of action of pezadeftide as a potent antifungal peptide. The abstract is below along with a link to the poster. Pezadeftide is a potent antifungal peptide with rapid...
Wilsons Research Report
Recently WILSONS published its initiation research report on Hexima Limited (ASX:HXL) with an OVERWEIGHT rating and a $0.75 12-month price target. View the full report (pdf)
NailMail Q4 2021
Hexima is proud to release its “NailMail” quarterly activities report for the quarter ended 31 December 2021. Achievements for the quarter include: Finishing the calendar year well capitalised with $14.3 million in cash at bank and R&D tax rebate receivable;...
Hexima featured at Edison Global Healthcare 2022
Hexima was pleased to be featured at Edison Open House: Global Healthcare 2022. Edison Group is an investment research, investor relations and consulting firm with offices in North America, Europe, the Middle East and AsiaPac. It hosts Edison Open House: Global...
Phil Rose appointed Chief Commercial Officer
Hexima announces the appointment of Phillip Rose as Chief Commercial Officer, based in the U.S. Phillip Rose reports to Michael Aldridge, Managing Director & CEO. Mr. Rose has over 30 years of leadership experience in the pharmaceutical industry, including...